# Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Source: https://onco.cc/trials/nct06249048/  
OnCo record `nct06249048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Strand Therapeutics Inc., now recruiting.

## Summary

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab is a phase 1/2 interventional study registered as NCT06249048 by Strand Therapeutics Inc., with 108 participants planned, started 2024-05-03 and due to reach its primary completion in 2027-05. Interventions recorded: STX-001 and Keytruda®.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06249048
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab
- Sponsor: Strand Therapeutics Inc.
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT06249048: https://clinicaltrials.gov/study/NCT06249048

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Strand Therapeutics](https://onco.cc/companies/strand-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06249048.json